Q-omics provides the consensus-scored POSTN profile across patient tissues and cancer cell-line models. POSTN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, POSTN is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, POSTN protein abundance shows 24,371 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where POSTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POSTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POSTN survival associations across molecular data types. POSTN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POSTN RNA expression–survival associations across cancer types. High POSTN expression shows unfavorable associations in KIRP, STAD, CESC, MESO, LGG and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for POSTN RNA expression.
This table summarizes POSTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POSTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POSTN shows higher tumor expression in HNSC, LUAD, KIRC, BLCA, LUSC and THCA. The HNSC box plot shows higher POSTN RNA expression in tumor versus normal tissue (log2 FC = +4.518, t-test p < 0.001).
This table shows molecular features associated with POSTN in patient tissues and cancer cell lines. In patient samples, POSTN shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, POSTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
